Share this video  

WCLC 2023 | Multi-modality treatment in thoracic PNET

Akif Turna, MD, PhD, Istanbul University-Cerrahpasa, Istanbul, Turkey, discusses the benefits of multi-modality treatment for patients with thoracic primitive neuroectodermal tumours (PNETs). PNETs are rare cancers often seen in young adults and middle-aged men. Thoracic PNETs are particularly aggressive, hence multi-modality treatment is the main strategy to increase patient survival. The analysis of different treatment modalities and their effect on survival in thoracic PNET associated neoadjuvant chemoradiotherapy with better survival. Results also suggested that tumour size can be an effective prognostic factor with smaller tumours indicating a more promising survival rate. Prof. Turna emphasises that patients with large thoracic PNETs respond well to chemoradiotherapy and, if their tumours can be down-staged, their survival rates can improve. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.